Effects of Repeated Eyelid Injections with Botulinum Toxin A on Innervation of Treated Muscles in Patients with Blepharospasm

References

• Fahn S. Blepharospasm, a form of focal dystonia. Adv Neurol. 1988;49:125–33.
   PubMedGoogle Scholar
• Bradley EA, Hodge DO, Bartley GB. Benign essential blepharospasm among residents of Olmstead County, Minnesota, 1976-1995: an epidemiologic study. Ophthal Plast Reconstr Surg. 2003;19:177–81.
   PubMed Web of Science ®Google Scholar
• Defazio G, Livrea P. Epidemiology of primary blepharospasm. Mov Disord. 2002;17:7–12.
   PubMed Web of Science ®Google Scholar
• Defazio G, Abbruzzese G, Livrea P, Berardelli A. Epidemiology of primary dystonia. Lancet Neurol. 2004;3:673–78. doi:10.1016/S1474-4422(04)00907-X.
   PubMed Web of Science ®Google Scholar
• Scott AB, Rosenbaum A, Collins CC. Pharmacologic weakening of extraocular muscles. Invest Ophthalmol. 1973;12(12):924–27.
   PubMedGoogle Scholar
• Scott AB, Kennedy RA, Stubbs HA. Botulinum A toxin injection as a treatment for blepharospasm. Arch Ophthalmol. 1985;103:347–50.
   PubMedGoogle Scholar
• Naumann M, Jankovic J. Safety of botulinum toxin type A: a systematic review and meta-analysis. Curr Med Res Opin. 2004;20:981–90. doi:10.1185/030079904125003962.
   PubMed Web of Science ®Google Scholar
• MacAndie K, Kemp E. Impact on quality of life of botulinum toxin treatments for essential blepharospasm. Orbit. 2004;23:207–10. doi:10.1080/01676830490506041.
   PubMedGoogle Scholar
• Lee RM, Chowdhury HR, Hyer JN, Smith HB, Jones CA. Patient-reported benefit from botulinum toxin treatment for essential blepharospasm: using 2 assessment scales. Ophthal Plast Reconstr Surg. 2013;29:196–97. doi:10.1097/IOP.0b013e3182805a2a.
   PubMed Web of Science ®Google Scholar
• Blasi J, Chapman ER, Link E, Binz T, Yamasaki S, De Camilli P, Südhof TC, Niemann H, Jahn R. Botulinum neurotoxin A selectively cleaves the synaptic protein SNAP-25. Nature. 1993;365:160–63. doi:10.1038/365160a0.
   PubMed Web of Science ®Google Scholar
• Raciborska DA, Charlton MP. Retention of cleaved synaptosome-associated protein of 25kDa (SNAP-25) in neuromuscular junctions: a new hypothesis to explain persistence of botulinum A poisoning. Can J Physiol Pharmacol. 1999;77:679–88.
   PubMed Web of Science ®Google Scholar
• Hopkins WG, Brown MC. The distribution of nodal sprouts in a paralysed or partly denervated mouse muscle. Neuroscience. 1982;7:37–44.
   PubMed Web of Science ®Google Scholar
• Pamphlett R. Early terminal and nodal sprouting of motor axons after botulinum toxin. J Neurol Sci. 1989;92:181–92.
   PubMed Web of Science ®Google Scholar
• Holds JB, Alderson K, Fogg SG, Anderson RL. Motor nerve sprouting in human orbicularis oculi muscle after botulinum A injection. Invest Ophthalmol Vis Sci. 1990;31:964–67.
   PubMed Web of Science ®Google Scholar
• Alderson K, Holds JB, Anderson RL. Botulinum-induced alteration of nerve-muscle interactions in the human orbicularis oculi following treatment for blepharospasm. Neurology. 1991;41:1800–05.
   PubMed Web of Science ®Google Scholar
• Harrison AR, Berbos Z, Zaldivar RA, Anderson BC, Semmer M, Lee MS, McLoon LK. Modulating neuromuscular junction density changes in botulinum toxin treated orbicularis oculi muscle. Invest Ophthalmol Vis Sci. 2011;52:982–86. doi:10.1167/iovs.10-6427.
   PubMed Web of Science ®Google Scholar
• Harrison AR, Anderson BC, Thompson LV, McLoon LK. Myofiber length and three-dimensional localization of NMJs in normal and botulinum toxin-treated adult extraocular muscles. Invest Ophthalmol Vis Sci. 2007;48:3594–601. doi:10.1167/iovs.06-1239.
   PubMed Web of Science ®Google Scholar
• Ababneh OH, Cetinkaya A, Kulwin DR. Long-term efficacy and safety of botulinum toxin A injections to treat blepharospasm and hemifacial spasm. Clin Exp Ophthalmol. 2014;42:254–61. doi:10.1111/ceo.12165.
   PubMed Web of Science ®Google Scholar
• Holland RL, Brown MC. Nerve growth in botulinum toxin poisoned muscles. Neuroscience. 1981;6:1167–79.
   PubMed Web of Science ®Google Scholar
• Brown MC, Hopkins WG, Keynes RJ. Comparison of effects of denervation and botulinum toxin paralysis on muscle properties in mice. J Physiol. 1982;327:29–37.
   PubMed Web of Science ®Google Scholar
• Simpson LL. The effects of acute and chronic botulinum toxin treatment on receptor number, receptor distribution and tissue sensitivity in rat diaphragm. J Pharmcol Exp Ther. 1977;200:343–51.
   PubMed Web of Science ®Google Scholar
• Bambrick L, Gordon T. Acetylcholine receptors and sodium channels in denervated and botulinum-toxin-treated adult rat muscle. J Physiol. 1987;382:69–86.
   PubMed Web of Science ®Google Scholar
• Thesleff S, Molgó J, Tågerud S. Trophic interrelations at the neuromuscular junction as revealed by the use of botulinal neurotoxins. J Physiol (Paris). 1990;84:167–73.
   PubMedGoogle Scholar
• Lander T, Wirtschafter JD, McLoon LK. Orbicularis oculi muscle fibers are relatively short and heterogeneous in length. Invest Ophthalmol Vis Sci. 1996;37:1732–39.
   PubMed Web of Science ®Google Scholar
• Mayr R, Gottschall J, Gruber H, Neuhuber W. Internal structure of cat extraocular muscle. Anat Embryol. 1975;148:25–34.
   PubMedGoogle Scholar
• Kupfer C. Motor innervation of extraocular muscle. J Physiol. 1960;153:522–26.
   PubMed Web of Science ®Google Scholar
• Happak W, Burggasser G, Gruber H. Histochemical characteristics of human mimic muscles. J Neurol Sci. 1988;83:25–35.
   PubMed Web of Science ®Google Scholar
• McLoon LK, Wirtschafter JD. Regional differences in the orbicularis oculi muscle: conservation between species. J Neurol Sci. 1991;104:197–202.
   PubMed Web of Science ®Google Scholar
• Kjellgren D, Thornell LE, Anderson J, Pedrosa Domellöf F. Myosin heavy chain isoforms in human extraocular muscles. Invest Ophthalmol Vis Sci. 2003;44:1419–25.
   PubMed Web of Science ®Google Scholar
• Hassan SM, Jennekens FG, Veldman H. Botulinum toxin-induced myopathy in the rat. Brain. 1995;118:533–45. doi:10.1093/brain/118.2.533.
   PubMed Web of Science ®Google Scholar
• Williams SA, Reid S, Elliott C, Shipman P, Valentine J. Muscle volume alterations in spastic muscles immediately following botulinum toxin type-A treatment in children with cerebral palsy. Dev Med Child Neurol. 2013;55:813–20. doi:10.1111/dmcn.12200.
   PubMed Web of Science ®Google Scholar
• Ward SR, Minamoto VB, Suzuki KP, Hulst JB, Bremner SN, Lieber RL. Recovery of rat muscle size but not function more than 1 year after a single botulinum toxin injection. Muscle Nerve. 2018;57:435–41. doi:10.1002/mus.25707.
   PubMed Web of Science ®Google Scholar
• Ansved T, Odergren T, Borg K. Muscle fiber atrophy in leg muscles after botulinum toxin type A treatment of cervical dystonia. Neurology. 1997;48:1440–42.
   PubMed Web of Science ®Google Scholar
• Korfage JA, Wang J, Lie SH, Langenbach GE. Influence of botulinum toxin on rabbit jaw muscle activity and anatomy. Muscle Nerve. 2012;45:684–91. doi:10.1002/mus.23229.
   PubMed Web of Science ®Google Scholar
• Kim NH, Park RH, Park JB. Botulinum toxin type A for the treatment of hypertrophy of the masseter muscle. Plast Reconstr Surg. 2010;125:1693–170536. doi:10.1097/PRS.0b013e3181d0ad03.
   PubMed Web of Science ®Google Scholar
• Porter JD, Strebeck S, Capra NF. Botulinum-induced changes in monkey eyelid muscle. Comparison with changes seen in extraocular muscle. Arch Ophthalmol. 1991;109:396–404.
   PubMedGoogle Scholar
• Horn AK, Porter JD, Evinger C. Botulinum toxin paralysis of the orbicularis oculi muscle. Types and time course of alterations in muscle structure, physiology and lid kinematics. Exp Brain Res. 1993;96:39–53.
   PubMed Web of Science ®Google Scholar
• Borodic GE, Ferrante R. Effects of repeated botulinum toxin injections on orbicular oculi muscle. J Clin Neuroophthal. 1992;12:121–27.
   PubMedGoogle Scholar
• Rogozhin AA, Pang KK, Bukharaeva E, Young C, Slater CR. Recovery of mouse neuromuscular junctions from single and repeated injections of botulinum neurotoxin A. J Physiol. 2008;3163–2182. doi:10.1113/jphysiol.2008.153569.
   PubMed Web of Science ®Google Scholar
• Caroni P, Schneider C, Kiefer MC, Zapf J. Role of muscle insulin-like growth factors in nerve sprouting: suppression of terminal sprouting in paralyzed muscle by IGF-binding protein 4. J Cell Biol. 1994;125:893–902.
   PubMed Web of Science ®Google Scholar
• Booth CM, Kemplay SK, Brown MC. An antibody to neural cell adhesion molecule impairs motor nerve terminal sprouting in a mouse muscle paralysed with botulinum toxin. Neuroscience. 1990;35:85–91.
   PubMed Web of Science ®Google Scholar
• Schäfer R, Wernig A. Polyclonal antibodies against NCAM reduce paralysis-induced axonal sprouting. J Neurocytol. 1998;27:615–24.
   PubMedGoogle Scholar
• Langenfeld-Oster B, Faissner A, Irintchev A, Wernig A. Polyclonal antibodies against NCAM and tenascin delay endplate reinnervation. J Neurocytol. 1994;23:591–604.
   PubMedGoogle Scholar